TMC-114 (Tibotec).
Tibotec (formerly Tibotec-Virco) is developing TMC-114 as a potential treatment for HIV-1 infection. In February 2001, TMC-126 was revealed as the series prototype, from which TMC-114 was developed. Because of its improved antiviral and superior pharmacokinetic properties, TMC-114 was selected for clinical development. Phase II trials of TMC-114 are underway.
Shurtleff
Amy C
AC
Department of Molecular Virology, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD 21702, USA. Amy.Shurtleff@DET.AMEDD.ARMY.MIL
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000069454:Darunavir; D006801:Humans; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D013449:Sulfonamides; D000069454:Darunavir